Biotechnology in Europe
Published: August 2013 · Publisher: MarketLine
Biotechnology in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
Biotechnology in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Europe biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
*The European biotechnology market had total revenues of $79.4bn in 2012, representing a compound annual growth rate (CAGR) of 11.5% between 2008 and 2012.
*Life sciences companies are increasingly targeting emerging markets such as China, India, Brazil, and others to supplement sales in the mature markets of U.S. and Europe.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 8% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $116.8bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Europe
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Europe
Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Europe biotechnology market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Europe economy
Key Questions Answered
What was the size of the Europe biotechnology market by value in 2012?
What will be the size of the Europe biotechnology market in 2017?
What factors are affecting the strength of competition in the Europe biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up Europe's biotechnology market?
Biotechnology in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Europe biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
*The European biotechnology market had total revenues of $79.4bn in 2012, representing a compound annual growth rate (CAGR) of 11.5% between 2008 and 2012.
*Life sciences companies are increasingly targeting emerging markets such as China, India, Brazil, and others to supplement sales in the mature markets of U.S. and Europe.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 8% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $116.8bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Europe
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Europe
Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Europe biotechnology market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Europe economy
Key Questions Answered
What was the size of the Europe biotechnology market by value in 2012?
What will be the size of the Europe biotechnology market in 2017?
What factors are affecting the strength of competition in the Europe biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up Europe's biotechnology market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
#N/A
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Boehringer Ingelheim GmbH 19
Merck & Co., Inc. 23
Amgen, Inc. 26
AstraZeneca PLC 29
F. Hoffmann-La Roche Ltd 33
Appendix 36
Methodology 36
Industry associations 37
Related research 37
LIST OF TABLES
Table 1: Europe biotechnology market value: $ billion, 2008–12 8
Table 2: Europe biotechnology market category segmentation: $ billion, 2012 9
Table 3: Europe biotechnology market geography segmentation: $ billion, 2012 10
Table 4: Europe biotechnology market value forecast: $ billion, 2012–17 11
Table 5: Boehringer Ingelheim GmbH: key facts 19
Table 6: Boehringer Ingelheim GmbH: key financials ($) 20
Table 7: Boehringer Ingelheim GmbH: key financials (€) 20
Table 8: Boehringer Ingelheim GmbH: key financial ratios 21
Table 9: Merck & Co., Inc.: key facts 23
Table 10: Merck & Co., Inc.: key financials ($) 24
Table 11: Merck & Co., Inc.: key financial ratios 24
Table 12: Amgen, Inc.: key facts 26
Table 13: Amgen, Inc.: key financials ($) 27
Table 14: Amgen, Inc.: key financial ratios 27
Table 15: AstraZeneca PLC: key facts 29
Table 16: AstraZeneca PLC: key financials ($) 30
Table 17: AstraZeneca PLC: key financial ratios 31
Table 18: F. Hoffmann-La Roche Ltd: key facts 33
Table 19: F. Hoffmann-La Roche Ltd: key financials ($) 34
Table 20: F. Hoffmann-La Roche Ltd: key financials (CHF) 34
Table 21: F. Hoffmann-La Roche Ltd: key financial ratios 34
LIST OF FIGURES
Figure 1: Europe biotechnology market value: $ billion, 2008–12 8
Figure 2: Europe biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: Europe biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: Europe biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in Europe, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in Europe, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in Europe, 2012 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in Europe, 2012 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in Europe, 2012 17
Figure 10: Drivers of degree of rivalry in the biotechnology market in Europe, 2012 18
Figure 11: Boehringer Ingelheim GmbH: revenues & profitability 21
Figure 12: Boehringer Ingelheim GmbH: assets & liabilities 22
Figure 13: Merck & Co., Inc.: revenues & profitability 25
Figure 14: Merck & Co., Inc.: assets & liabilities 25
Figure 15: Amgen, Inc.: revenues & profitability 28
Figure 16: Amgen, Inc.: assets & liabilities 28
Figure 17: AstraZeneca PLC: revenues & profitability 31
Figure 18: AstraZeneca PLC: assets & liabilities 32
Figure 19: F. Hoffmann-La Roche Ltd: revenues & profitability 35
Figure 20: F. Hoffmann-La Roche Ltd: assets & liabilities 35
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Boehringer Ingelheim GmbH 19
Merck & Co., Inc. 23
Amgen, Inc. 26
AstraZeneca PLC 29
F. Hoffmann-La Roche Ltd 33
Appendix 36
Methodology 36
Industry associations 37
Related research 37
LIST OF TABLES
Table 1: Europe biotechnology market value: $ billion, 2008–12 8
Table 2: Europe biotechnology market category segmentation: $ billion, 2012 9
Table 3: Europe biotechnology market geography segmentation: $ billion, 2012 10
Table 4: Europe biotechnology market value forecast: $ billion, 2012–17 11
Table 5: Boehringer Ingelheim GmbH: key facts 19
Table 6: Boehringer Ingelheim GmbH: key financials ($) 20
Table 7: Boehringer Ingelheim GmbH: key financials (€) 20
Table 8: Boehringer Ingelheim GmbH: key financial ratios 21
Table 9: Merck & Co., Inc.: key facts 23
Table 10: Merck & Co., Inc.: key financials ($) 24
Table 11: Merck & Co., Inc.: key financial ratios 24
Table 12: Amgen, Inc.: key facts 26
Table 13: Amgen, Inc.: key financials ($) 27
Table 14: Amgen, Inc.: key financial ratios 27
Table 15: AstraZeneca PLC: key facts 29
Table 16: AstraZeneca PLC: key financials ($) 30
Table 17: AstraZeneca PLC: key financial ratios 31
Table 18: F. Hoffmann-La Roche Ltd: key facts 33
Table 19: F. Hoffmann-La Roche Ltd: key financials ($) 34
Table 20: F. Hoffmann-La Roche Ltd: key financials (CHF) 34
Table 21: F. Hoffmann-La Roche Ltd: key financial ratios 34
LIST OF FIGURES
Figure 1: Europe biotechnology market value: $ billion, 2008–12 8
Figure 2: Europe biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: Europe biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: Europe biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in Europe, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in Europe, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in Europe, 2012 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in Europe, 2012 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in Europe, 2012 17
Figure 10: Drivers of degree of rivalry in the biotechnology market in Europe, 2012 18
Figure 11: Boehringer Ingelheim GmbH: revenues & profitability 21
Figure 12: Boehringer Ingelheim GmbH: assets & liabilities 22
Figure 13: Merck & Co., Inc.: revenues & profitability 25
Figure 14: Merck & Co., Inc.: assets & liabilities 25
Figure 15: Amgen, Inc.: revenues & profitability 28
Figure 16: Amgen, Inc.: assets & liabilities 28
Figure 17: AstraZeneca PLC: revenues & profitability 31
Figure 18: AstraZeneca PLC: assets & liabilities 32
Figure 19: F. Hoffmann-La Roche Ltd: revenues & profitability 35
Figure 20: F. Hoffmann-La Roche Ltd: assets & liabilities 35
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.